Predictive In Vitro Models

Over 60% of drugs that fail during clinical development do so for reasons of safety. The cost implications of being able to accurately predict in vivo toxicity and pharmacokinetics are huge, including:

Reduced attrition
Improved pipeline planning
Less time spent in animals
Overall, finding problems with drugs that would only otherwise be uncovered during expensive clinical phases.

Predictive in vitro models provide a fantastic opportunity to more accurately predict clinical outcomes preclinic, maximizing R&D productivity and minimizing cost. But there are still some major barriers preventing their widespread adoption:

What in vitro models are available?
How do you assess their predictive capability?
How do you achieve validation of new models?
How do you best apply these models to accurately predict safety and pharmacokinetics in vivo?

Developed in collaboration with R&D leaders from Pfizer, Novartis, GSK, Roche, Abbot, Merck, Genentech, Harvard Stem Cell Institute , MIT and others, Predictive In Vitro Models for Drug Development, Boston 28th – 29th September, is designed to increase your preclinical predictive capability specifically around safety and pharmacokinetics. The meeting will bring together safety and pharmacokinetics experts from big pharma and biotech to explore how in vitro models can transform your ability to predict clinical outcomes and increase your organization's productivity.

What's on the agenda for Predictive in Vitro Models in Drug Development?

Eliminating clinical failure due to toxicity by developing accurate compound safety predictions as well as exploring the potential of 3D hepatocyte models and embryonic stem cell derived human hepatocytes as new tools for in vitro toxicity testing.

Developing fit for purpose in vitro models to accurately predict in vivo drug activity – capitalizing on new platforms and advances in predictive in vitro test development, including stem cells, 3D cell cultures, tissue engineering and human tissue.

Improving R&D decision making by successfully validating new in vitro models and improving the correlation between in vitro and in vivo data
Developing effective partnerships between platform providers and drug developers to accurately assess predictive potential of new models
Eliminating the need for clinical drug interaction studies by generating accurate in vitro data.

Developing in vitro assays to assess transporter-related pharmacogenetic risk in vivo

Improving understanding of in vivo pharmacokinetics preclinic by incorporating a systems biology approach

Who's the meeting for?
This meeting has been designed to provide invaluable information to drug developers to find the best ways of utilizing advances in in vitro modelling to enhance preclinical predictive capability, including those in the fields of:

Preclinical Development
In Vitro technologies
Toxicology
Safety Assessment
Safety pharmacology
Drug metabolism and pharmacokinetics (DMPK)
ADME
Stem Cell research
Assay development
Tissue/biological engineering
Translational Medicine

All will benefit from this frank and open discussion of the latest modelling platforms that will accelerate preclinical drug development.

Further Information: http://www.invitro-models.com/